HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Speaker at International Conference on Clinical & Translational Oncology 2026 - Jianhua Luo
Keynote Presentation (In-Person)
Jianhua Luo, University of Pittsburgh School of Medicine, United States

Hepatocellular carcinoma is one of the most lethal malignancies for humans. Assessing the clinical outcomes of HCC remains challenging. In this study, a panel of 20 fusion genes in 200 hepatocellular carcinoma (HCC) samples was analyzed to predict the recurrence and survival rate [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Shinya Tajima
Keynote Presentation (In-Person)
Shinya Tajima, National Hospital Organization Shizuoka Medical Centre, Japan

We would like to present a only case study: However, our important findings might lead to help the interpretations of “tumour microenvironment (TME)”. We herein presenting about 70-year-old female. She presented with a palpable mass in the upper inner quadrant of t [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Sergey Suchkov
Keynote Presentation (In-Person)
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). The concept of PPM is becoming increasingly relevant for cancer treatment, moving from the ‘one-size-fits-all’ [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Sergey Suchkov
Oral Presentation (In-Person)
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). In this sense, Personalized & Precision Oncology (PPO) is an innovative approach to cancer management and is oriented t [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Floyd Taub
Oral Presentation (In-Person)
Floyd Taub, aiGENE, Inc., United States

Modern oncology commonly requires sequential treatment; however, trials for approval typically do not include direct testing of sequences. Adaptive trials and Sequential Multiple Assignment Randomized Trial (SMART) trials are often of approved drugs and are large, slow, complex, [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Ahora Chehri
Oral Presentation (In-Person)
Ahora Chehri, Johann Wolfgang Goethe-Universität Frankfurt am Main (Universität Frankfurt am Main), Germany

Purpose of the study: This study aims to analyze global research trends and emerging themes in the application of stem cell biology for cancer therapy. The intent is to map the intellectual landscape and identify key areas of focus and collaboration from 2020 to 2024.  Me [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jinhua Wang
Oral Presentation (In-Person)
Jinhua Wang, Jiangsu Cancer Hospital, China

Adult-type ovarian Granulosa Cell Tumor (AGCT) is a rare low-grade malignant sex cord-stromal tumor, accounting for 2–5% of all ovarian malignancies, with 95% of cases occurring in middle-aged women aged 45–55 years. Cases in young patients ≤25 years old are extrem [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Paulraj S
Oral Presentation (In-Person)
Paulraj S, Chennai Snake Park Trust, India

The origin, growth and spread of various cancers follow some common regulatory paths. Although hundreds of genes are involved in this process, most of these paths are initiated and controlled by one dominant and central factor, the Hypoxia Inducible Factor 1α (HIF-1α) [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Maria Isabel Sollozo Dupont
Oral Presentation (In-Person)
Maria Isabel Sollozo Dupont, National Institute of Perinatology Isidro Espinosa de los Reyes, Mexico

Breast cancer is a major public health issue since it is the most common cause of death from malignant neoplasms in women over 25 around the world, especially in low-income countries where death rates are higher. In Mexico, preventative efforts are made harder by the fact that sc [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Ramalingam K
Oral Presentation (In-Person)
Ramalingam K, Mediclone Biotech Research Centre, India

This study aims to investigate the profound interplay between lifestyle, environmental factors, and the psychological burden of a cancer diagnosis. While medical advancements have improved survival rates, the diagnosis frequently triggers a severe "fear psychosis," char [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Dongyao Zhang
Oral Presentation (In-Person)
Dongyao Zhang, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China

Objective: Ovarian cancer (OC) immunosuppression severely limits therapeutic efficacy. While peripheral neural tumor regulation is recognized, the central nervous system's (CNS) role in modulating the tumor immune microenvironment (TIME) remains unclear. We aimed to map the p [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Floyd Taub
Oral Presentation (In-Person)
Floyd Taub, aiGENE, Inc., United States

Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA), found in blood and urine, have firmly established themselves as key analytes for the diagnosis of various cancers and for defining therapy. Primary sequence and epigenetic markers within cfDNA are key in screening and monit [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Anbuganapathi G
Oral Presentation (In-Person)
Anbuganapathi G, Anbu Hospital, India

In the Indian context, the Siddha system of medicine (one of the oldest traditional systems, primarily from South India) is increasingly utilized as a powerful complementary and alternative medicine (CAM) for cancer. This is one of the approved medical systems under the Ministry [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jing Sheng
Oral Presentation (In-Person)
Jing Sheng, Shanghai Pulmonary Hospital, Tongji University, China

Purpose: To determine whether CT predictors of visceral pleural invasion (VPI) differ by tumor–pleural relationship in part-solid lung adenocarcinoma and to develop interpretable models for pleural-attached and pleural-tag nodules. Methods: This retrospective study include [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jian Hong Lin
Poster Presentation (In-Person)
Jian Hong Lin, Hualien Tzu Chi Hospital, Taiwan

Ferroptosis is an iron-dependent form of regulated cell death characterized by excessive lipid peroxidation and oxidative damage to cellular and organelle membranes. Because lysosomes are membrane-bound organelles that are particularly susceptible to oxidative injury, ferroptosis [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Manmohan Agrawal
Keynote Presentation (Virtual)
Manmohan Agrawal, Pushpadi Cancer Care Centre, India

The prognosis of breast cancer remains unpredictable despite of frequent change in treatment protocol since last few decades. As we understand the heterogenous nature of the disease, complex tumor biology etc. the treatment protocols have changed. There is an unprecedented transf [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Paulo Cesar De Morais
Keynote Presentation (Virtual)
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil

In this keynote lecture, exotic nanomagnetic materials (magnetic nanorings - MNRs) will be introduced as a very promising material for application in magnetic hyperthermia (MHT), an advanced cancer therapeutic modality. The chemical synthesis and the characterization of the [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Yan Leyfman
Keynote Presentation (Virtual)
Yan Leyfman, NYP- Meyer Cancer Center, United States

Background: Large language models (LLMs) are increasingly used in oncology clinical workflows; however, real-world clinician adoption has outpaced formal institutional guidance and systematic safety validation. Existing evaluations often rely on aggregate performance metrics, whi [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Michael Thompson
Keynote Presentation (Virtual)
Michael Thompson, University of Toronto, Canada

Currently, the primary methods for detecting the ovarian cancer (OC) are transvaginal ultrasound (TVUS) and blood tests for the cancer antigen 125 (CA125) biomarker. However, these methods alone are not suitably sensitive or specific to identify the disease in its early, asymptom [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Rajvir Dahiya
Keynote Presentation (Virtual)
Rajvir Dahiya, University of California San Francisco, United States

Current screening methods—radiological imaging, DNA-based tests, and pathological assessments—often fail to detect malignancies at early stages. Despite technological advances, gene-based diagnostics specifically designed for early cancer detection remain limited. To [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Arthi Roy
Oral Presentation (Virtual)
Arthi Roy, Pabna Medical College, Bangladesh

Background: Colorectal carcinoma (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide. Emerging evidence suggests that vitamin D, beyond its classical role in bone metabolism, may influence carcinogenesis through its effects on cell proliferation [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Arthi Roy
Oral Presentation (Virtual)
Arthi Roy, Pabna Medical College, Bangladesh

Background: Breast cancer remains the most commonly diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide. Despite advances in diagnosis and treatment, its global burden continues to rise, highlighting the need for modifiable prognostic factor [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Victor Chigbundu Nwaiwu
Oral Presentation (Virtual)
Victor Chigbundu Nwaiwu, Health Sciences University, United Kingdom

Today, artificial intelligence (AI) is one of the hottest buzzwords in technology. It is at the center of the global technological revolution, envisaged to replace or enhance human capabilities in the coming times. With AI projected to be one of the major disrupting forces in the [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Ratan Kumar Sarkar
Oral Presentation (Virtual)
Ratan Kumar Sarkar, Independent Researcher, India

The cancer drugs(SBDD) generally blocks cell signaling but it also blocks disintegration of lunar gravity(705) and electronic time(27 or 27*0.0019 = 0.0513 or 513) that would not co-exists driving to protein synthesis until neutralization of 27 e.g. 609(AFP) + 291 = 900 where 609 [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Saumya Pandey
Oral Presentation (Virtual)
Saumya Pandey, Indira IVF Hospital, India

Objectives: Inflammation is a hallmark of HPV-mediated cervical cancer; Matrix metalloproteinase [MMP]-2 and tissue inhibitor of metalloproteinase [TIMP]-2 are emerging as pivotal players in inflammation and carcinogenesis. My study aimed to evaluate the role of MMP-2 (-735C>T [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Eleni Petsalaki
Oral Presentation (Virtual)
Eleni Petsalaki, University of Crete, Greece

Chromatin bridges are strands of incompletely segregated DNA connecting the anaphase poles or daughter nuclei. Chromatin bridges can arise from incompletely replicated DNA, defective resolution of DNA catenates or dicentric chromosomes which are formed by chromosome fusions. If u [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Stephan Bodis
Oral Presentation (Virtual)
Stephan Bodis, University Zurich, Switzerland

Introduction: Patient information during therapies and follow-up needs to be constantly adapted for a flawless integration of complex oncologic therapy concepts into clinical routine. This is a key step for an optimal, individualized patient information and guidance and, ultimate [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Bing Shen
Oral Presentation (Virtual)
Bing Shen, Tongji University, China

Bladder cancer is one of the most common malignancies worldwide, and early diagnosis and regular follow-up are crucial for improving patient prognosis. Cystoscopy and tissue biopsy, the gold standards for diagnosing bladder cancer, are invasive and may result in complications. Ur [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Omar Al Qaisi
Oral Presentation (Virtual)
Omar Al Qaisi, Al-Zaytoonah University, Jordan

Background   Armed conflicts severely disrupt cancer care delivery, destroying infrastructure and limiting access to essential diagnostics and treatments. Evidence on service challenges, adaptations, and policy implications remains fragmented. Methods   This scopin [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Omar Al Qaisi
Oral Presentation (Virtual)
Omar Al Qaisi, Al-Zaytoonah University, Jordan

Selenium deficiency is associated with impaired immunity and leukemogenesis. Selenium compounds exhibit antiproliferative and proapoptotic effects in leukemic models, indicating therapeutic potential. However, no comprehensive review has assessed selenium’s impact on leukem [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jose Luis Braga De Aquino
Oral Presentation (Virtual)
Jose Luis Braga De Aquino, Pontifical Catholic University, Brazil

Although malignant neoplasms of the esophagus remain a very common disease, their diagnosis might often come late. This issue combined with excessive weight loss due to dysphagia and the association with cardiopulmonary diseases resulting from excessive tobacco use, makes patient [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jose Luis Braga De Aquino
Oral Presentation (Virtual)
Jose Luis Braga De Aquino, Pontifical Catholic University, Brazil

Even through the esophageal cancer has innumerable treatment options, its prognosis is still unsettled. Because esophagectomy is rarely curative, others therapies, such as chemorradiation emerging in advanced disease followed or not surgery. The salvage esophagectomy is an altern [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Soumya
Oral Presentation (Virtual)
Soumya, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), India

Will be Updated Soon...

Speaker at International Conference on Clinical & Translational Oncology 2026 - Shilpa S Dhar
Oral Presentation (Virtual)
Shilpa S Dhar, MD Anderson Cancer Center, United States

Patient-derived organoids (PDOs) provide a unique opportunity to study cancer as an evolving, heterogeneous disease while retaining clinically relevant features of individual tumors. We are developing integrated organoid platforms spanning Barrett’s esophagus (BE), esophage [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Phillip Bretz
Oral Presentation (Virtual)
Phillip Bretz, Visionary Breast Center, United States

Breast cancer is one of the last things that bring to mind the word beautiful. But what if there was something beautiful about breast cancer missing from the equation of diagnosis and treatment for all this time? What if there was a way to diagnose nascent tumors before they atta [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Amirhosein Maali
Oral Presentation (Virtual)
Amirhosein Maali, Qazvin University of Medical Sciences, Iran (Islamic Republic of)

Chimeric antigen receptor T-cell therapy has shown significant clinical benefit, particularly in hematologic malignancies; however, conventional CAR-T platforms still face important limitations, including fixed antigen specificity, antigen escape, limited controllability, and saf [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Catarina Chati
Poster Presentation (Virtual)
Catarina Chati, Faculdade São Leopoldo Mandic Campinas, Brazil

Background: Lung cancer remains a major cause of cancer-related mortality worldwide. In Brazil, despite advances in tobacco-control policies, mortality patterns may vary according to sociodemographic and regional characteristics, highlighting important inequalities in the burden [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Yi Chih Liang
Poster Presentation (Virtual)
Yi Chih Liang, National Sun Yat-Sen University, Taiwan

Background: Upper tract urothelial carcinoma (UTUC) is a distinct malignancy arising from the renal pelvis or ureter. Globally, UTUC represents 5–10% of urothelial carcinomas, but in Taiwan its incidence reaches up to 30%, the highest reported worldwide. This epidemiologica [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Sabura Banu Urundai Meeran
Keynote Presentation (Virtual)
Sabura Banu Urundai Meeran, Saveetha Engineering College, India

Early and accurate cancer detection remains one of the most pressing challenges in clinical oncology, and deep convolutional neural networks (CNNs) have shown strong promise in automating diagnosis from medical images. However, the diagnostic performance of CNN architectures such [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Poulami Khan
Keynote Presentation (Virtual)
Poulami Khan, Asutosh College, India

Despite recent advancements in research, cancer metastasis and recurrence continue to be the primary causes of treatment failure. In this context, tumor progression and treatment resistance are progressively inferred as consequences of complex dynamic crosstalk within the tumor m [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - George Zachos
Keynote Presentation (Virtual)
George Zachos, University of Crete, Greece

Chromatin bridges are strings of mis-segregated chromatin connecting the anaphase poles or daughter nuclei in mitotic cell division and can arise from incomplete DNA replication or decatenation, or from dicentric chromosomes generated by end-to-end chromosome fusions. Chromatin b [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Mostafa Mesbah Mahmoud Sabbah
Keynote Presentation (Virtual)
Mostafa Mesbah Mahmoud Sabbah, Gaza Oncology Center, Israel

Background: Continuity of cancer care is essential for safe and effective treatment. However, maintaining continuous oncology services can be particularly challenging in resource-limited and crisis-affected settings. In Gaza, oncology patients and healthcare professionals face m [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Thomas J Webster
Keynote Presentation (Virtual)
Thomas J Webster, Brown University, United States

Nanomedicine is the use of nanomaterials to improve disease prevention, detection, and treatment which has resulted in hundreds of FDA approved medical products. While nanomedicine has been around for several decades, new technological advances are pushing its boundaries. For exa [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Mohammed Al Awadh
Oral Presentation (Virtual)
Mohammed Al Awadh, University of Bahri, Sudan

Background: Predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer is essential for personalizing treatment. AI-assisted ultrasound has emerged as a promising non invasive approach, yet a systematic review specifically evaluating the di [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Can Küçük
Oral Presentation (Virtual)
Can Küçük, Dokuz Eylül University, Turkey

Multiple myeloma (MM) is a relatively frequent type of hematological malignancy that consists of proliferation of abnormal plasma cells in the bone marrow. MGUS and SMM are asymptomatic precursor conditions that can potentially transition to multiple myeloma. Previous reports ind [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Vladan Radosavljevic
Oral Presentation (Virtual)
Vladan Radosavljevic, Military Medical Academy, Serbia

Background or Introduction: Chemical carcinogens classified by the International Agency for Research on Cancer (IARC) as Group 1 very probably contribute to cancer occurrence in over 13.5 million people and death from cancer in over seven million people. In percent, chemical elem [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Venketesh K Panda
Oral Presentation (Virtual)
Venketesh K Panda, Kalinga Institute of Industrial Technology, Deemed to be University, India

Melanoma has emerged as a paradigm for modern cancer therapy, demonstrating how molecularly targeted treatments and immunotherapy can transform outcomes in advanced malignancy. Despite these advances, therapeutic resistance, tumor heterogeneity, immune evasion, and disease recurr [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Nermeen Mohamed Elbakary
Oral Presentation (Virtual)
Nermeen Mohamed Elbakary, Egyptian Atomic Energy Authority, Egypt

Background Diethylnitrosamine (DEN) induces hepatic injury and can promote hepatocarcinogenesis. Quercetin (QR) and low-dose gamma irradiation (LDR) have been explored as hepatoprotective and anticancer-modulating agents, but their combined effects in DEN-induced liver cancer ha [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jagmohan Lal Meena
Oral Presentation (Virtual)
Jagmohan Lal Meena, ACTREC - Tata Memorial Centre, India

Cancer and its treatments frequently result in physical, cognitive, psychosocial, and functional impairments that adversely affect participation, independence, and quality of life. Occupational Therapy (OT) plays a pivotal role across the continuum of cancer care, extending from [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Hamza Saad
Oral Presentation (Virtual)
Hamza Saad, University of Central Missouri, United States

The challenges posed by lung cancer are immense. It is one of the most serious diseases, health-wise, due to various factors affecting patient outcomes, such as demographic, environmental, behavioral, treatment-related, and clinical factors. With the increasing availability of mu [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Swetha Manjappa
Oral Presentation (Virtual)
Swetha Manjappa, Movius, India

Artificial intelligence is increasingly being introduced into healthcare to address the growing burden of repetitive clinical and operational activities. However, the key question is not whether artificial intelligence can replace clinical work, but which activities can be respon [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Mame Diarra Samb
Poster Presentation (Virtual)
Mame Diarra Samb, Cheikh Anta Diop University of Dakar, Senegal

Background: The cancers of the upper aerodigestive tract and oral cancers in particular represent a major global public health problem, with particularly high mortality rates in low- and middle-income countries. These cancers rank 16th among malignant tumors and are the 15th le [....] » Read More

Facebook Twitter XTwitter Youtube
Whatsapp